Immutep Stock

Immutep Liabilities

The The Liabilities of Immutep (IMM.AX) as of Aug 9, 2026 is 13.35 M AUD. In the previous year, The Liabilities was 12.06 M AUD — a change of 10.70% (higher).

Liabilities

13.35 MAUD

YoY

10.70%

Last updated:

In 2026, Immutep's total liabilities amounted to 13.35 M AUD, a 10.70% difference from the 12.06 M AUD total liabilities in the previous year.

Access this data via the Eulerpool API

Immutep Stock analysis

What does Immutep do? Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company was founded in 2001 and is headquartered in Sydney, Australia. The history of Immutep began with the discovery of a new type of T-cell receptor, known as lymphocyte activation gene-3 (LAG-3) receptors, which are involved in the activation of T-cells. The company used this knowledge to develop a platform of immunotherapeutics based on the stimulation of LAG-3 receptors, with the goal of enhancing the body's immune response against cancer and autoimmune diseases. Immutep's business model is based on the development and commercialization of immunotherapeutics that target LAG-3 receptors. The company focuses on the clinical development of therapeutics targeting various stages of cancer, such as lung cancer, prostate cancer, and breast cancer. Additionally, the company is also developing therapeutics for the treatment of autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and Crohn's disease. Immutep is divided into various divisions to coordinate its activities in the areas of research and clinical development. These divisions include clinical development, research and development, and the production of immunotherapeutics. In the clinical development division, Immutep focuses on demonstrating the safety and efficacy of its immunotherapeutics in the treatment of cancer and autoimmune diseases. The company conducts clinical trials to evaluate the effectiveness of its therapeutics and obtain regulatory approval. Immutep's research and development department focuses on developing innovative immunotherapeutics based on LAG-3 receptors. The company has developed several patented technologies that enhance the effectiveness of the therapeutics and increase the body's tolerance to them. Immutep also operates a production division specializing in the manufacturing of immunotherapeutics. The company has production facilities in Europe and Asia, allowing it to distribute its therapeutics worldwide. The company offers a range of immunotherapeutics based on the stimulation of LAG-3 receptors. These therapeutics have been specifically developed for the treatment of cancer and autoimmune diseases and have the potential to enhance the body's immune response against these conditions. Immutep's products include IMP321, an immunotherapeutic specifically developed for the treatment of prostate cancer, and IMP701, an immunotherapeutic specifically developed for the treatment of lung cancer. Additionally, the company has several new therapeutics in clinical development, including IMP761 for the treatment of systemic lupus erythematosus and IMP731 for the treatment of Crohn's disease. Immutep is a leading company in the development of immunotherapeutics based on LAG-3 receptors. The company has a strong pipeline of therapeutics in clinical development and is well-positioned to benefit from the growing demand for immunotherapeutics for the treatment of cancer and autoimmune diseases. With its patented technologies and expertise in clinical development of immunotherapeutics, Immutep is well-equipped to grow and solidify its position as a leading company in this field. Immutep is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Immutep's Liabilities

Immutep's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Immutep's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Immutep's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Immutep's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Immutep’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Immutep stock

The Liabilities of Immutep is 13.35 M AUD in 2026.

The Liabilities of Immutep changed from 12.06 M AUD to 13.35 M AUD, representing a 10.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Immutep since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Immutep historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Immutep

All Key Metrics — Immutep